Consensus Revvity, Inc.

Stocks

RVTY

US7140461093

Advanced Medical Equipment & Technology

Market Closed - NYSE 00:00:02 18/09/2026 +04			5-day change	1st Jan Change
146.73 ^USD	+0.69%		+21.32%	+51.66%

09-15	Revvity, Inc. Presents at 2026 Global Healthcare Conference, Sep-15-2026 09:05 AM
09-14	Revvity, Inc. Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-14-2026 08:30 AM

Evolution of the Average Target: Revvity, Inc.

Evolution of the Target Price: Revvity, Inc.

Changes in Analyst Recommendations: Revvity, Inc.

6b72694f19bdf.DCG1pq1FNbLn26c4zKR1d_lZVYVrIVm4z04FzW1HUgQ.Pnj3k_UVXIGqgdBhuclDG4gYEOY4EWmO4hs3hw8lHnY5cdjBzi9lhaif5g~dfa21cb6a5b590f6c6415d5cae5e338e

Analysts' recommendations: Revvity, Inc.

09-09	UBS Downgrades Revvity to Neutral From Buy, Adjusts Price Target to $140 From $120	MT
09-04	KeyBanc Adjusts Price Target on Revvity to $165 From $125, Maintains Overweight Rating	MT
09-04	Analyst recommendations: Microsoft, DocuSign, Intuit, Lululemon Athletica, Zscaler…
09-03	Baird Adjusts Price Target on Revvity to $144 From $131, Keeps Outperform Rating	MT
09-01	Revvity Faces Growth Challenges Amid Rising Competition, RBC Says	MT
09-01	RBC Initiates Revvity at Sector Perform With $135 Price Target	MT
08-05	Bernstein Adjusts Price Target on Revvity to $120 From $115, Maintains Market Perform Rating	MT
08-05	Evercore ISI Adjusts Price Target on Revvity to $126 From $125, Maintains Outperform Rating	MT
08-05	Jefferies Adjusts Price Target on Revvity to $112 From $102, Maintains Hold Rating	MT
08-05	Barclays Adjusts Price Target on Revvity to $115 From $105, Maintains Equalweight Rating	MT
08-05	JPMorgan Adjusts Price Target on Revvity to $110 From $90	MT
08-05	Stifel Adjusts Price Target on Revvity to $110 From $100	MT
08-05	Analyst recommendations: Palantir Technologies, McDonald's, Booking Holdings, Arista Networks, Amgen...
07-15	TD Cowen Adjusts Price Target on Revvity to $130 From $120, Maintains Buy Rating	MT
07-13	Baird Adjusts Price Target on Revvity to $128 From $117, Maintains Outperform Rating	MT
07-06	Evercore ISI Adjusts Price Target on Revvity to $125 From $110	MT
05-04	Baird Adjusts Revvity Price Target to $125 From $129, Maintains Outperform Rating	MT
04-14	Barclays Downgrades Revvity to Equalweight From Overweight, Adjusts Price Target to $95 From $118	MT
04-13	Goldman Sachs Adjusts Price Target on Revvity to $95 From $110, Maintains Neutral Rating	MT
04-13	TD Cowen Adjusts Price Target on Revvity to $115 From $124, Maintains Buy Rating	MT
04-06	Evercore ISI Adjusts Revvity Price Target to $108 From $118, Maintains Outperform Rating	MT
03-31	JPMorgan Adjusts Price Target on Revvity to $96 From $105, Maintains Neutral Rating	MT
02-03	Wells Fargo Adjusts Price Target on Revvity to $110 From $107	MT
02-03	TD Cowen Adjusts Revvity PT to $124 From $120	MT
02-03	Baird Adjusts Price Target on Revvity to $129 From $123	MT

More recommendations

Other Advanced Medical Equipment & Technology

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	REVVITY, INC.					-13.46%
	THERMO FISHER SCIENTIFIC, INC.					-0.51%
	DANAHER CORPORATION					+9.95%
	INTUITIVE SURGICAL, INC.					+24.6%
	BOSTON SCIENTIFIC CORPORATION					+41.2%
	SIEMENS HEALTHINEERS AG					+18.67%
	EDWARDS LIFESCIENCES CORPORATION					+13.08%
	AGILENT TECHNOLOGIES, INC.					+13.83%
	WATERS CORPORATION					+5.75%
	ILLUMINA, INC.					-11.48%
	Average					+10.16%
	Weighted average by Cap.					+11.08%